CVS Health Corporation (CVS)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 9/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 1.27% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Aetna 2027 Medicare plans offer reliable, affordable access to care & member support
- How Much Downside Is Left In CVS Health Stock?
- Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health
- Hunger Action Month: Supporting Healthier Communities Through Better Access to Nutritious Food
- UnitedHealth and Humana cutting Medicare Advantage plans in 2027
- Why McKesson Stock Soared More Than 5% Higher Today
- Why McKesson (MCK) Stock Is Trading Up Today
- Cardinal Health Extends CVS Health Pharmaceutical Distribution Agreement Through 2032
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for CVS Health Corporation.
Full CVS Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.